Mission BioCapital

Advancing novel cell therapies for T-cell malignancies.

#Therapeutics

Developing a new approach to treating multiple sclerosis.

#Therapeutics

Developing novel therapeutics by engineering tissue-selective growth factors.

#Therapeutics

Developing small molecule HDAC6 inhibitors for human disease treatment.

#Therapeutics

Discovering therapies targeted to the thymus for immune tolerance.

#Therapeutics

Developing therapeutics for undruggable targets.

#Therapeutics

Developing therapeutics that modulate chromatin networks in disease.

#Therapeutics

Combining synthetic biology and machine learning for next-generation therapeutics.

#Therapeutics

Building cell and gene ventures centered on product development.

#Therapeutics

Developing immunomodulatory therapies for cancer and autoimmune diseases.

#Therapeutics

Developing antibody-based targeted therapies against disease-driving proteins.

#Therapeutics

Advancing therapies to restore immune homeostasis in autoimmune diseases.

#Therapeutics

A company creation engine focused on de-risking early-stage projects.

#Therapeutics

Developing inhibitors targeting cancer signaling pathways.

#Therapeutics

Developing next-generation cell-therapies using targeted epigenetic modifiers.

#Therapeutics

Building a portfolio of neurodegeneration companies for transformative neuroscience.

#Therapeutics

Building a portfolio of neurodegeneration companies for transformative neuroscience.

#Therapeutics

Drugging the undruggable by manipulating interactions with adaptor protein 14-3-3.

#Therapeutics

Developing a new class of medicines based on enzyme biology discoveries.

#Therapeutics

Creating the next generation of animal-based food substitutes from plants.

#Consumer Products

Developing precision medicine to reverse cancer cell immortality.

#Therapeutics

Reprogramming natural killer cells to attack cancer cells.

#Therapeutics

Developing therapies for rare diseases of protein and lipid glycosylation.

#Therapeutics

Targeting mitochondria to develop therapies for neurodegenerative disease.

#Therapeutics

Built an engineering platform for inborn errors of metabolism.

#Therapeutics

Aims to restore vision in patients with vision loss, acquired by Novartis.

#Therapeutics

Advancing novel targeted medicines for frontotemporal dementia.

#Therapeutics

Innovating immune cell reprogramming, acquired by Sanofi.

#Therapeutics

Developing local, sustained drug delivery for solid tumors.

#Therapeutics

Drugging the myofibroblast to halt and reverse fibrosis.

#Therapeutics

Harnessing RNA therapeutics for gene therapy.

#Therapeutics

Harnessing nature's diversity for next-gen CRISPR products.

#Diagnostics

Revolutionizing treatment of neurogenic inflammation.

#Therapeutics

Developing precision medicines for ALS and neurologic diseases.

#Therapeutics

Leveraging AI for antibody therapeutics, acquired by Absci.

#Therapeutics

Offers at-home health & lab testing solutions.

#Diagnostics

Pioneering non-invasive sensors for glucose monitoring.

#Diagnostics

Pioneering cellular agriculture for seafood.

#Agriculture and Climate

Developed immunomodulatory molecules, acquired by Merck.

#Therapeutics

Developing products to promote skin health.

#Consumer Products

Creating agile food systems with crop solutions.

#Agriculture

Creating tools for next-gen membrane biology discoveries.

#Lab Tools

Developing targeted radiotherapeutics for cancer.

#Therapeutics

Developing bio-chemical signals for daily use.

#Diagnostics

Developing localized cancer therapy modalities.

#Drug Delivery

Transforming vaccine delivery with the MIMIX patch.

#Drug Delivery

Developing therapies to restore gut health.

#Therapeutics

Developing cancer immunotherapies, acquired by Gilead Sciences.

#Therapeutics

Developing medicines to fight opioid dependence.

#Therapeutics

Developed CAR-T cell technologies, acquired by Gilead Sciences.

#Therapeutics

Revolutionizing intraoperative histology with laser imaging.

#Diagnostics

Harnessing the immune system for neurodegenerative disease, IPO in 2019.

#Therapeutics

Improving treatment methods for kidney stones.

#Devices

Oncology-focused small molecule drug discovery.

#Therapeutics

Developing therapeutics for fibrotic diseases.

#Therapeutics

Developing non-opioid treatments for pain.

#Therapeutics

Developed single cell western blot system, acquired by Bio-Techne.

#Lab Tools

Synthetic biology company, IPO in 2021.

#Consumer Products

Developing genome-edited cell therapies, IPO in 2021.

#Therapeutics

Developing cell permeable macrocyclic peptide therapeutics.

#Therapeutics

Developing a surgical device to prevent airway collapse during sleep.

#Devices

Developed therapies targeting the complement system, acquired by Bioverativ.

#Therapeutics

Developing translation regulator inhibitors, IPO in 2013.

#Therapeutics

Creating products for more comfortable contact lenses.

#Consumer Products

Using patient B cell responses for antibody discovery, IPO in 2019.

#Therapeutics

Pioneering a surgical device for GI tract interventions.

#Devices

Developing sustainable materials inspired by nature.

#Consumer Products

Developing microfluidic tools for cellular analysis.

#Lab Tools

Developed BTK inhibitors for autoimmune diseases, acquired by Sanofi.

#Therapeutics

Developed therapies for neurodegenerative disease, acquired by Bristol-Myers Squibb.

#Therapeutics

Developing small molecule drugs for cancer treatment.

#Therapeutics

Developed protein conjugation technologies, acquired by Catalent Pharma Solutions.

#Therapeutics